Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cyclosporine A 0.05% eye drops to prevent ocular GVHD-related dry eye
ChiCTR2100054583Phase 4Recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Jul 2021
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of cyclosporine in ocular graft-versus-host disease (oGVHD) and dry eye syndrome (DED) (2 arms), sponsored by Sun Yat-sen Memorial Hospital. Primary endpoint: Type II tear secretion test. Started Jul 2021; status: recruiting.
02
Drugs
cyclosporine
03
Conditions
ocular graft-versus-host disease (oGVHD)dry eye syndrome (DED)
Beyond the preview
Go deeper on ChiCTR2100054583.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100054583.